A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Inclusion Criteria: * Adult patients, \>/=18 years of age * Diagnosis of diabetes mellitus, type 2 within 12 months prior to screening * Patients who have not received a anti-hyperglycemic medication for at least 12 weeks prior to screening and for not longer than 3 consecutive months in the past * HbA1c \>/=7% and \</=9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit * Fasting plasma glucose \</=240 mg/dL at pre-randomization visit * Agreement to maintain diet and exercise habits during the study Exclusion Criteria: * Patients with Type 1 diabetes mellitus, secondary diabetes, diabetes resulting from pancreatic injury, or acute metabolic diabetic complications within the past 6 months * Any previous treatment with thiazolidinedione or a dual peroxisome proliferator activated receptor (PPAR) agonist * Any body weight lowering or lipoprotein-modifying therapy within 12 weeks prior to screening (except stable dose of statin) * Symptomatic congestive heart failure classified as New York Heart Association class II-IV at screening